Disclosed are antibodies that bind to Epithelial Cell Adhesion Molecule (Ep CAM) and display certain advantages over known antibodies which bind to Ep CAM, for example, the antibodies of the invention show good affinity, good cross-reactivity profiles and excellent ADCC and CDCC activity. Antibodies comprising specific heavy and light chain CDRs are disclosed. The invention thus relates to these antibodies and all uses thereof, in particular in the treatment of cancer. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer. Advantageous immunoconjugate compositions and methods using the new anti-Ep CAM antibodies are also provided.
